Wolfgang Miesbach on FRONTIER2 Data: Mim8 Prophylaxis Achieves a Median ABR of Zero in Hemophilia A
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn:
“FRONTIER2 delivers impressive ASH 52-week data presented by Lentz Steven: Adults and adolescents with haemophilia A maintained robust bleed protection with Mim8 prophylaxis, regardless of inhibitor status or prior treatment regimen:
- Median ABR of zero across extension period (weeks 26-52)
QW dosing: estimated mean ABR 1.28 [95% CI: 0.78–2.08]
QM dosing: estimated mean ABR 1.54 [95% CI: 0.92–2.59] - Prior on-demand patients saw dramatic 97–99% ABR reduction
- CFC prophylaxis patients achieved 42–48% further ABR reduction compared to prior treatment
Safety profile and over 270+ patient-years of exposure:
- No thromboembolic events
- No hypersensitivity reactions
- No coagulation abnormalities
- Injection-site reactions in <1% of administrations (all mild, transient)
- 82–84% of AEs mild; 66–88% unrelated to Mim8sciencehub.novonordisk
Anti-Mim8 antibodies in 7% of patients—all low/medium titer, zero clinical impact
What is Mim8?
MFactor VIIIa mimetic bispecific antibody bridges activated FIX/FX on platelet surfaces
Half-life: ~1 month (enables QW or QM dosing flexibility)
Potency: 13–18× more effective than emicizumab preclinically
Take away
96% completion rate through 52 weeks reflects both tolerability and patient satisfaction. The consistency of efficacy with sustained zero median bleeds across 6+ months—combined with minimal safety signals—establishes Mim8 as a durable, flexible prophylactic option for haemophilia A. FRONTIER4 extension study now enrolling.”
Read more posts from Wolfgang Miesbach on Hemostasis Today.
-
Apr 10, 2026, 18:22Chris Hillis: Reflections on My Term as President of the Canadian Hematology Society
-
Apr 10, 2026, 17:59Michelle Leona Cecil: Representing Microhealth at The Coalition for Hemophilia B Annual Symposium
-
Apr 10, 2026, 17:47Lucie Raskin: Comparing VTE Risk in Hormonal Contraceptives at NTHC 2026
-
Apr 10, 2026, 17:39Diverse Voices But Shared Mission – Day 1 of EHC Youth Leadership Workshop
-
Apr 10, 2026, 17:30Make Your Mark at the World Stroke Congress 2026 – World Stroke Organization
-
Apr 10, 2026, 17:23Sofie Abels: Implications for Targeted Screening for Thrombophilia in Young Stroke Patients
-
Apr 10, 2026, 17:08Armghan Ans: 3 Questions Worth Sitting with If You Work in Stroke AI
-
Apr 10, 2026, 17:03William Wallace: Vitamin C Is More Than ”Immune Support”
-
Apr 10, 2026, 16:58Wolfgang Miesbach: Greater Symptom Burden in Women with Bleeding Disorders – Insights from Irish Data